2019年冠状病毒病(COVID-19)
疾病
医学
系统药理学
中医药
大流行
传染病(医学专业)
药理学
传统医学
计算生物学
替代医学
生物
药品
病理
作者
Hongbo Chen,Xiaohong Zhang,Jiaying Li,Zhe Xu,Yunjun Luo,Rundong Chai,Ruzhen Luo,Yuhong Bian,Qing Liu
出处
期刊:ACS omega
[American Chemical Society]
日期:2023-07-24
卷期号:8 (30): 26871-26881
标识
DOI:10.1021/acsomega.3c01489
摘要
Objective: Infections and death have been a part of our daily lives since the COVID-2019 pandemic outbreak in 2019, and the societal and economic consequences have lingered for an unanticipated duration. Novel and effective treatments are still desperately needed around the world to combat the infection. Here, we discovered a novel traditional Chinese medicine formula (TCMF) to potentially combat COVID-19 through reverse systematic pharmacology (disease → targets → TCMF → disease). Methods: Combining Integrative network pharmacology and the traditional Chinese medicine (TCM) theory, a TCMF for COVID-19 was identified. In silico physiological interactions between herbs and disease hub targets were validated by molecular docking and dynamics simulation. Results: Based on disease-related gene/pathway targets and a combination of reverse pharmacology and TCM meridian tropism theory, a COVID-19-associated herb database was constructed. A new TCMF, including Gancao, Baitouweng, Congbai, and Diyu (GBCD), was discovered for anti-COVID-19 therapy. The KEGG and GO analyses of 49 intersecting genes suggested that GBCD could combat COVID-19 through antiviral, antiinflammation, immunoregulation, and cytoprotection activities. Moreover, these possible effects were validated through docking and MD simulation. Conclusions: To the best of our knowledge, this study is the first to combine reverse pharmacology and meridian tropism theories for TCMF development, and a novel herbal combination, GBCD, was discovered for anti-COVID-19 therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI